On June 24, 2024, Kelly Romano, Director at Athira Pharma Inc (ATHA, Financial), purchased 42,400 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 80,715 shares of Athira Pharma Inc.
Athira Pharma Inc, a biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegeneration.
The shares were bought at a price of $2.36 per share, valuing the transaction at approximately $100,064. The purchase has increased the insider's stake in the company significantly. Over the past year, the insider has bought a total of 42,400 shares and has not sold any shares.
The transaction history at Athira Pharma Inc shows a trend with 2 insider buys and 8 insider sells over the past year. This recent purchase by the insider might indicate a positive outlook on the company's future prospects.
The current market cap of Athira Pharma Inc stands at $82.982 million. Investors often monitor insider buys as they can provide insights into how the company's executives view the stock's valuation and future performance.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
